[CAS NO. 1110766-97-6] Lusutrombopag
PRODUCTS SPECIFICATIONS [1110766-97-6]
DESCRIPTION [1110766-97-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 591.55 |
| Molecular Formula | C29H32Cl2N2O5S |
| SMILES | O=C(O)/C(C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OCCCCCC)C)=C3OC)=CS2)=O)C=C1Cl |
1 Publications Citing Use of MCE
Summary
Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
In Vitro
Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02389621 | Shionogi|Shionogi Inc. |
Chronic Liver Disease|Thrombocytopenia
|
June 15, 2015 | Phase 3 |
| NCT01129024 | Shionogi|Shionogi Inc. |
Immune Thrombocytopenia
|
April 29, 2010 | Phase 2 |
| NCT03897413 | Shionogi|Shionogi Inc. |
Healthy Volunteer
|
November 6, 2009 | Phase 1 |
| NCT01054443 | Shionogi|Shionogi Inc. |
Immune Thrombocytopenia (ITP)
|
March 18, 2010 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 33 mg/mL ( 55.79 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6905 mL | 8.4524 mL | 16.9047 mL |
| 5 mM | 0.3381 mL | 1.6905 mL | 3.3809 mL |
| 10 mM | 0.1690 mL | 0.8452 mL | 1.6905 mL |
Synonyms